BioAtla, Inc. (NASDAQ:BCAB - Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 5,240,000 shares, a growth of 17.2% from the September 30th total of 4,470,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the short-interest ratio is presently 4.4 days.
Analyst Ratings Changes
Separately, JMP Securities restated a "market outperform" rating and set a $5.00 target price on shares of BioAtla in a research report on Monday, September 16th.
View Our Latest Stock Analysis on BioAtla
Institutional Trading of BioAtla
A number of institutional investors have recently made changes to their positions in BCAB. Price T Rowe Associates Inc. MD bought a new stake in shares of BioAtla in the first quarter worth about $45,000. Vontobel Holding Ltd. bought a new stake in shares of BioAtla in the 3rd quarter worth approximately $28,000. Ground Swell Capital LLC purchased a new position in shares of BioAtla during the second quarter valued at approximately $33,000. Valmark Advisers Inc. bought a new position in shares of BioAtla during the second quarter valued at approximately $34,000. Finally, Rinkey Investments bought a new position in shares of BioAtla during the second quarter valued at approximately $35,000. Hedge funds and other institutional investors own 77.23% of the company's stock.
BioAtla Stock Performance
BioAtla stock traded up $0.10 during mid-day trading on Monday, hitting $2.09. 693,072 shares of the company traded hands, compared to its average volume of 832,884. BioAtla has a one year low of $1.14 and a one year high of $4.02. The stock has a market cap of $100.56 million, a price-to-earnings ratio of -0.84 and a beta of 1.06. The stock has a fifty day moving average price of $1.86 and a 200-day moving average price of $1.91.
BioAtla (NASDAQ:BCAB - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.01. During the same quarter in the prior year, the business posted ($0.75) EPS. Sell-side analysts predict that BioAtla will post -1.52 EPS for the current year.
BioAtla Company Profile
(
Get Free Report)
BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
Featured Stories
Before you consider BioAtla, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioAtla wasn't on the list.
While BioAtla currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.